Novolog (Pharm UP 1966) Ltd. (IL:NVLG)
TASE:NVLG
Want to see IL:NVLG full AI Analyst Report?
NVLG Stock Chart & Stats
126.20
>-0.01(-0.31%)
At close: 4:00 PM EST
126.20
>-0.01(-0.31%)
Day’s Range― - ―
52-Week Range91.20 - 154.63
Previous CloseN/A
Volume351.22K
Average Volume (3M)641.09K
Market Cap
₪497.08M
Enterprise Value562.60M
Total Cash (Recent Filing)₪121.77M
Total Debt (Recent Filing)₪183.20M
Price to Earnings (P/E)155.9
Beta0.62
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.05%
Share Statistics
EPS (TTM)0.80
Shares Outstanding510,874,760
10 Day Avg. Volume285,794
30 Day Avg. Volume641,093
Financial Highlights & Ratios
PEG Ratio-1.74
Price to Book (P/B)1.80
Price to Sales (P/S)0.36
P/FCF Ratio-18.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthA roughly 0.5x debt-to-equity ratio indicates a conservative capital structure that supports durability through downturns. This level of leverage preserves financial flexibility for refinancing, working capital needs and strategic investments, reducing default risk over a multi‑month horizon.
Historical Cash GenerationThe company has demonstrated the ability to generate substantial operating and free cash flow in recent years, implying an inherently cash‑generative business model. That track record supports capacity to rebuild liquidity, service debt, and fund reinvestment if operating trends normalize.
Profitability Track RecordRepeated profit years show the underlying business model can produce margins and earnings. This track record indicates recoverable cost structures and operational levers management can deploy to restore profitability over a multi‑month cycle when demand conditions improve.
Bears Say
Negative Cash Flow In 2025A shift to negative operating and free cash flow materially weakens liquidity and forces reliance on financing or asset dispositions. Sustained negative cash generation constrains reinvestment, dividend capacity and debt servicing, elevating funding risk over the next several months if not reversed.
Sharp Revenue & Earnings DeclineA marked drop in top-line and net income signals structural demand or pricing pressure that compresses margins and scale economics. Such a swing undermines sustainable profitability and raises the probability that operating leverage will continue to amplify earnings downside absent durable revenue stabilization.
Asset Base ContractionA meaningful reduction in total assets points to shrinking operational capacity or asset sales to shore up liquidity. This contraction reduces long‑term revenue-generating capacity and, when paired with earnings pressure, increases exposure to leverage and limits strategic optionality.
Novolog News
NVLG FAQ
What was Novolog (Pharm UP 1966) Ltd.’s price range in the past 12 months?
Novolog (Pharm UP 1966) Ltd. lowest stock price was 91.20 and its highest was 154.63 in the past 12 months.
What is Novolog (Pharm UP 1966) Ltd.’s market cap?
Novolog (Pharm UP 1966) Ltd.’s market cap is ₪497.08M.
When is Novolog (Pharm UP 1966) Ltd.’s upcoming earnings report date?
Novolog (Pharm UP 1966) Ltd.’s upcoming earnings report date is May 20, 2026 which is in 18 days.
How were Novolog (Pharm UP 1966) Ltd.’s earnings last quarter?
Novolog (Pharm UP 1966) Ltd. released its earnings results on Nov 12, 2025. The company reported 0.8 earnings per share for the quarter, beating the consensus estimate of N/A by 0.8.
Is Novolog (Pharm UP 1966) Ltd. overvalued?
According to Wall Street analysts Novolog (Pharm UP 1966) Ltd.’s price is currently Overvalued.
Does Novolog (Pharm UP 1966) Ltd. pay dividends?
Novolog (Pharm UP 1966) Ltd. pays a Quarterly dividend of 1.957 which represents an annual dividend yield of 3.05%. See more information on Novolog (Pharm UP 1966) Ltd. dividends here
What is Novolog (Pharm UP 1966) Ltd.’s EPS estimate?
Novolog (Pharm UP 1966) Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Novolog (Pharm UP 1966) Ltd. have?
Novolog (Pharm UP 1966) Ltd. has 510,874,760 shares outstanding.
What happened to Novolog (Pharm UP 1966) Ltd.’s price movement after its last earnings report?
Novolog (Pharm UP 1966) Ltd. reported an EPS of 0.8 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Novolog (Pharm UP 1966) Ltd.?
Currently, no hedge funds are holding shares in IL:NVLG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Novolog (Pharm UP 1966) Ltd.
Novolog (Pharm-Up 1966) Ltd provides healthcare services in Israel. It offers medical devices to healthcare institutions and patients in their homes; and medical logistics services to pharmaceutical and medical device companies. The company also produces and disseminates medical content and tools to the general public and medical community; and develops personalized treatment programs and initiates home visits by nurses. In addition, it provides health and medical process management services for corporations; and supplies sterilization services using ethylene oxide gas for medical and laboratory products, as well as offers direct access to health and wellness ecosystem for international corporations. The company is based in Modi'in-Maccabim-Re'ut, Israel.